Removal of parvovirus B19 from hemoglobin solution by nanofiltration

被引:12
作者
Abe, H
Sugawara, H
Hirayama, J
Ihara, H
Kato, T
Ikeda, H
Ikebuchi, K
机构
[1] Hokkaido Red Cross Ctr, Nishi Ku, Sapporo, Hokkaido 0630002, Japan
[2] Terumo Co, Ctr Res & Dev, Nakai, Kanagawa 2590151, Japan
来源
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY | 2000年 / 28卷 / 05期
关键词
D O I
10.3109/10731190009118582
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Parvovirus B19 (B19), which may contaminate red cell components for blood transfusion, is known to be resistant to several viral inactivation methods. To increase the safety of hemoglobin solutions as a source of red cell substitutes, we investigated the removal of parvovirus B19 from hemoglobin solution using nanofiltration. The hemoglobin solution spiked with parvovirus B19 was tangentially filtered using the BMM-35 filter (mean pore size of 35 nm) followed by BMM-15. The parvovirus B19 of 10(8.5) PT50 (median PCR titer)10 mu L was not changed after the BMM-35 filtration. However, the BMM-15 filtration decreased the parvovirus B19 from 10(8.3-8.7) PT50 to 10(1.3-2.2) PT50, indicating more than 6 log(10) reduction. When the initial parvovirus B19 of 10(6.0) PT50 was subjected to the BMM-15 filtration, the residual virus was 10(-0.3-0.5) PT50 or undetected in some fraction of the filtrate. Hemoglobin recovery was 70.4 +/- 3.4%. The ratio of methemoglobin was not changed during the filtration. These findings indicate that the BMM-15 filtration is a promising approach to prepare a safer hemoglobin solution for red cell substitutes.
引用
收藏
页码:375 / 383
页数:9
相关论文
共 16 条
[1]  
ABE H, 1995, ARTIF ORGAN TODAY, V5, P19
[2]   Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb™) for viral inactivation [J].
Azari, M ;
Ebeling, A ;
Baker, R ;
Burhop, K ;
Camacho, T ;
Estep, T ;
Guzder, S ;
Marshall, T ;
Rohn, K ;
Sarajari, R ;
Boose, JA ;
Gauvin, G ;
Horner, R ;
Lu, B ;
Pearson, L ;
Vacante, D .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1998, 26 (5-6) :577-582
[3]   HUMAN PARVOVIRUS-B19 INFECTION IN HEMOPHILIACS 1ST INFUSED WITH 2 HIGH-PURITY, VIRALLY ATTENUATED FACTOR-VIII CONCENTRATES [J].
AZZI, A ;
CIAPPI, S ;
ZAKVRZEWSKA, K ;
MORFINI, M ;
MARIANI, G ;
MANNUCCI, PM .
AMERICAN JOURNAL OF HEMATOLOGY, 1992, 39 (03) :228-230
[4]  
FRIEDMAN LI, 1994, BLOOD SUPPLY RISKS P, P139
[5]  
NAKAI K, 1992, Japanese Journal of Artificial Organs, V21, P318
[6]   LYSOPHOSPHATIDYLCHOLINE, A COMPONENT OF STROMAL PHOSPHOLIPIDS, AS A CANDIDATE VASOCONSTRICTIVE FACTOR IN STROMA-FREE HEMOGLOBIN [J].
NAKAI, K ;
MATSUDA, N ;
OHTA, T ;
AMANO, M ;
TAKAHASHI, TA ;
SAKUMA, I ;
KITABATAKE, A ;
ITO, S ;
NAKAZATO, Y ;
SEKIGUCHI, S .
ARTIFICIAL ORGANS, 1994, 18 (03) :198-205
[7]  
NAKAI K, 1995, ARTIFICIAL RED CELLS, P131
[8]   Development of Neo Red Cells (NRC) with the enzymatic reduction system of methemoglobin [J].
Ogata, Y ;
Goto, H ;
Kimura, T ;
Fukui, H .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1997, 25 (04) :417-427
[9]   EVALUATION OF A STROMA-FREE HEMOGLOBIN SOLUTION FOR USE AS A PLASMA EXPANDER [J].
RABINER, SF ;
HELBERT, JR ;
LOPAS, H ;
FRIEDMAN, LH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1967, 126 (06) :1127-+
[10]  
REED L. J., 1938, AMER JOUR HYG, V27, P493